Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.
Daniel Krappmann about his new Research Unit "Signaling and Translation" at Helmholtz Munich
Matthias Hebrok about his new Institute for Diabetes and Organoid Technology (IDOT) at Helmholtz Munich
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: